News Hub | News Direct

Education

Higher Education Preschool Primary/Secondary
Article thumbnail News Release

How Over-The-Counter Medicines Could Impact Your Blood Pressure

YourUpdateTV

Would it surprise you to know that nearly half of all adults in the country have elevated blood pressure, and most don’t even know it? Yet only 30% have spoken with a healthcare professional about the adverse effects some over-the-counter medicines can have on their blood pressure. Recently, Dr. Mitch Elkind, American Heart Association’s Chief Clinical Science Officer, conducted a satellite media tour to share precautionary measures that people with high blood pressure need to take before using over-the-counter medications, especially if they have pre-existing conditions or are on other medications. A video accompanying this announcement is available at: https://youtu.be/x7bVSA55fJ0 High blood pressure, (also referred to as hypertension) is when your blood pressure, the force of blood flowing through your blood vessels, is consistently too high. The best way to know if you have high blood pressure it is to have your blood pressure checked. How to use a home blood pressure monitor Be still. Discuss how to use your home blood pressure monitor with your health care professional. Don't smoke, drink caffeinated beverages or exercise within 30 minutes before measuring your blood pressure. Empty your bladder and ensure at least five minutes of quiet rest before measurements. Sit correctly. Sit with your back straight and supported (on a dining chair, rather than a sofa). Your feet should be flat on the floor and your legs should not be crossed. Your arm should be supported on a flat surface, such as a table, with the upper arm at heart level. Make sure the bottom of the cuff is placed directly above the bend of the elbow. Check your monitor's instructions for an illustration or have your health care professional show you how. Measure at the same time every day. It’s important to take the readings at the same time each day, such as morning and evening. It is best to take the readings daily, ideally beginning two weeks after a change in treatment and during the week before your next appointment. Take multiple readings and record the results. Each time you measure, take two readings one minute apart and record the results using a printable (PDF) tracker. If your monitor has built-in memory to store your readings, take it with you to your appointments. Some monitors may also allow you to upload your readings to a secure website after you register your profile. Don't take the measurement over clothes. If you get a high blood pressure reading If your blood pressure is higher than 180/120 mm Hg and you are experiencing signs of possible organ damage such as chest pain, shortness of breath, back pain, numbness/weakness, change in vision or difficulty speaking, do not wait to see whether your pressure comes down on its own. Call 911, as this is an emergency. A single high reading is not an immediate cause for alarm. If you get a reading that is slightly or moderately higher than normal, take your blood pressure a second time and write the results of the two measurements down. Consult your health care professional to verify if there’s a health concern or whether there may be any issues with your monitor. If your blood pressure readings suddenly exceed 180/120 mm Hg, wait five minutes and test again. If your readings are still unusually high, contact your health care professional immediately. You could be experiencing a hypertensive crisis. AHA recommendation The American Heart Association recommends home monitoring for all people with high blood pressure to help the health care professional determine whether treatments are working. Home monitoring, or self-measured blood pressure, is not a substitute for regular visits to your physician. If you have been prescribed medication to lower your blood pressure, don't stop taking your medication without consulting your health care professional, even if your blood pressure readings are in the normal range during home monitoring. Understanding Over-the-Counter (OTC) Medications and High Blood Pressure Look for warnings related to high blood pressure medication. Always read the labels on all over-the-counter medications, especially if you have high blood pressure, also known as hypertension. Look for warnings to those with high blood pressure and to those who take blood pressure medications. If you have high blood pressure and certainly if you are on prescription medication, consult your health care professional before taking any over-the-counter medications or supplements. Be careful with supplements or natural (naturopathic) remedies. There are no special pills, vitamins or drinks that can substitute for prescription medications and lifestyle modifications. Talk to your health care professional before taking any over-the-counter drug or supplement that claims to lower your blood pressure. They may not work as advertised and/or may interfere with other medications. In fact, some can even raise your blood pressure. Decongestants may raise your blood pressure. People with high blood pressure should be aware that the use of decongestants may raise blood pressure or interfere with the effectiveness of some prescribed blood pressure medications. Be aware of over-the-counter cold and flu preparations that contain decongestants as well. Discuss any medications you wish to use with your health care professional. Check the sodium content. Some over-the-counter medications are high in sodium, which can also raise blood pressure. Look at the active and inactive ingredients lists for words like “sodium” or “soda.” Note the amount of sodium in the medication. People with high blood pressure should consume less than 1,500 mg of sodium per day from all sources — one dose of some over-the-counter medications can contain more than a whole day’s allowance. Other drugs and substances that can raise your blood pressure include: Alcohol Amphetamines Antidepressants Atypical antipsychotics (for example, clozapine and olanzapine) Caffeine Cocaine Oral contraceptives Non-steroidal anti-inflammatory drugs, or NSAIDs (for example, ibuprofen and naproxen sodium) Systemic corticosteroids (for example, prednisone and methylprednisolone) Do not stop taking any prescribed medications without discussing with your health care professional. To learn more visit: heart.org/bptools About Talent Mitchell S. V. Elkind, MD, MS, FAAN, FAHA is a tenured Professor of Neurology and Epidemiology at Columbia University, and the Chief Clinical Science Officer at the American Heart Association as of September 2022. He received his medical degree from Harvard Medical School, and he trained in Internal Medicine at Brigham and Women’s Hospital and in Neurology at Massachusetts General Hospital, both in Boston, MA. He completed a fellowship in Vascular Neurology and Neuroepidemiology at Columbia University Medical Center. Dr. Elkind holds a Master’s degree in Epidemiology from Columbia’s Mailman School of Public Health. Dr. Elkind’s research focuses on stroke prevention, inflammatory and infectious biomarkers in stroke risk prediction, atrial cardiopathy, immune therapy for acute stroke, and vascular causes of cognitive aging. He is the second neurologist to serve as President of the American Heart Association (AHA) in its 100 year history, from 2020-2021. About the American Heart Association The American Heart Association is a relentless force for a world of longer, healthier lives. We are dedicated to ensuring equitable health in all communities. Through collaboration with numerous organizations and powered by millions of volunteers, we fund innovative research, advocate for the public’s health and share lifesaving resources. The Dallas-based organization has been a leading source of health information for nearly a century. Connect with us on heart.org, Facebook, X, or by calling 1-800-AHA-USA1. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

November 09, 2023 10:57 AM Eastern Standard Time

Video
Article thumbnail News Release

HKBU-led research discovers therapeutic potential of hyodeoxycholic acid for non-alcoholic fatty liver disease

Hong Kong Baptist University

HONG KONG SAR - Media OutReach - 8 November 2023 - A research led by Hong Kong Baptist University (HKBU) has discovered that hyodeoxycholic acid (HDCA), a bile acid generated in human intestine, can reduce fat accumulation and inflammation in the liver, demonstrating its strong therapeutic potential for non-alcoholic fatty liver disease (NAFLD). The research also found that HDCA's intervention in NAFLD works by reshaping the population of beneficial gut bacteria, which affects the metabolic interactions between the gut and the liver. The result highlighted the critical role of gut health in liver disease. The research findings have been published in the renowned scientific journal Cell Metabolism. HKBU researchers will coordinate a phase I and II clinical trial in the Mainland to evaluate the safety and efficacy of HDCA for patients with fatty liver disease and type 2 diabetes. 32% of adults suffer from NAFLD NAFLD is a leading cause of chronic liver disease, characterised by the build-up of excessive fat in liver cells that is not caused by alcohol consumption. Its global prevalence has been increasing over time. A meta-analysis in 2022 estimated that 32% of the adult population is affected by NAFLD. Some people with NAFLD can develop non-alcoholic steatohepatitis, which is marked by liver inflammation and may progress to cirrhosis and liver failure. Currently, there are no therapeutic drugs available for sale on the market for non-alcoholic steatohepatitis. A research led by Professor Jia Wei, Acting Dean and Chair Professor in Chinese Medicine and Systems Biology of the School of Chinese Medicine at HKBU, discovered that HDCA offers promising potential as a pharmaceutical intervention for NAFLD. "Our research is a significant stride forward in understanding the pathophysiology of NAFLD, and it offers a potential new avenue for therapeutic intervention," he said. Therapeutic effects of HDCA Professor Jia's team found that individuals with NAFLD have lower levels of HDCA compared to those without NAFLD. In a cohort consisting of 178 patients with NAFLD and 73 healthy individuals, hyocholic acid species, including HDCA and its major metabolite glycohyodeoxycholic acid, comprises 0.5% of the bile acids in NAFLD patients, which is significantly lower than the 2% in healthy individuals. This observation led the team to explore HDCA's potential therapeutic role. A series of controlled experiments were conducted to evaluate the therapeutic effect of HDCA. The team orally fed HDCA to mouse models with NAFLD for eight weeks. The results showed that HDCA markedly reduced excessive lipid droplets, and improved hepatic inflammation, oral glucose tolerance (i.e. the blood glucose level after oral intake of glucose), and insulin sensitivity (i.e. the sensitivity of the body to the effects of insulin which helps the glucose to enter into the cells for use) compared to the control group. The results revealed that HDCA alleviated NAFLD conditions and the risk factors of NAFLD such as type 2 diabetes and insulin resistance. Interestingly, the researchers found that HDCA did not exert its therapeutic effects on NAFLD by directly targeting liver cells. They evaluated the potential direct effect of HDCA on lipid accumulation in a mouse model. The results showed that lipid accumulation was barely affected by the HDCA. They hypothesised that HDCA induced gut microbiota alterations, which might contribute to the alleviation of NAFLD. HDCA reshapes gut microbiota The researchers observed that HDCA could improve the population of beneficial gut bacteria. Parabacteroides distasonis (P. distasonis), a member of the core microbiome in the human gut, sharply increased in the mouse model fed with high-fat food and administered with HDCA, compared with the control group fed with high-fat food only. The results revealed that HDCA provided a favorable environment for the thriving of P. distasonis, which regulates fatty acid metabolism as well as the hepatic bile acid synthesis pathways. "The study underscores the crucial role of the gut-liver metabolic axis in disease management. We hope that the research findings on HDCA and the clinical trial to be conducted in the Mainland will provide more insights into the treatment of fatty liver disease and non-alcoholic steatohepatitis," said Professor Jia. Professor Jia has also led a research project investigating the molecular connections between metabolic-associated fatty liver disease and type 2 diabetes mellitus, with a specific focus on host-gut microbiota interactions. The project has been awarded over HK$7.2 million in research funding from the Theme-based Research Scheme (13th round) under the Research Grants Council. Contact Details Christina Wu christinawu@hkbu.edu.hk

November 08, 2023 09:00 AM Eastern Standard Time

Image
Article thumbnail News Release

Asian University for Women partner with Cisco Networking Academy Program

Asian University for Women

HONG KONG SAR - Media OutReach - 8 November 2023 - Asian University for Women (AUW) and the world’s leading technology company Cisco signed an agreement that Cisco will provide access to Cisco Networking Academy Program, the company’s global IT and cybersecurity education program, skills-based career certifications, and cyber security training to selected students attending the university in Bangladesh. The collaboration aims to provide students the IT competencies they need to thrive in the workforce. This new partnership with Cisco Networking Academy Program will enable all AUW students to undertake digital training and gain certifications that will enhance career prospects with vital technical skills development. Courses include networking, cyber security, digital literacy, data science and programming, operating systems, and professional skills with hands-on practice opportunities. The university will roll out the program to all undergraduate and pre-undergraduate students, starting in December 2023, with an aim of equipping as many of the graduates with an array of practical certifications and necessary IT skills to become more effective in the workforce. AUW and Cisco signed the agreement at the Annual AUW Impact Event held at JW Marriott Hotel in Hong Kong on October 30 in front of hundreds of AUW Hong Kong-based supporters. “At AUW and our Support Foundation, we are dedicated to preparing high-potential women from underserved communities to become effective future leaders in their home countries after graduation,” said Lynne Anne Davis, board chairman of the AUW Support Foundation in Hong Kong. “We are deeply grateful to Cisco for generously equipping our students with the latest innovative tools, knowledge and technology to further boost the transformative power that an AUW education provides and set them up for success in their onward career journeys." About AUW Founded in 2008, AUW is a leading liberal arts and sciences institution located in Chittagong, Bangladesh. The University seeks to establish itself as the educational destination of choice for talented women from across the Asian continent and beyond, irrespective of their socio-economic background. AUW has a special mission to serve women from communities that have been historically disenfranchised or whose lives have been abruptly disrupted by civil war or political upheavals, and to offer them a world-class education. 1500 students from 17 countries currently attend AUW: Afghanistan, Bangladesh, Bhutan, Cambodia, China, India, Indonesia, Lao PDR, Myanmar, Nepal, Pakistan, Sri Lanka, Syria, Timor Leste, Vietnam, and Yemen. More than 85% of AUW students are on full or near-full scholarships funded by supporters from around the world. To learn more about Asian University for Women, please visit https://asian-university.org. AUW has already graduated over 1400 students from around Asia and the Middle East. Contact Details Daisy Nicholas +1 617-914-0500 Daisy.Nicholas@asian-university.org

November 08, 2023 09:00 AM Eastern Standard Time

Image
Article thumbnail News Release

Augmented Reality (AR) in the Classroom: Snap’s AR technology offers endless possibilities for creativity, engagement, and exploration.

YourUpdateTV

A video accompanying this announcement is available at: https://youtu.be/QEuZ5YDnkRQ Through the magic of augmented reality (AR), students can learn in an immersive and flexible environment no matter where they are, helping them to better understand and engage with complex STEM concepts. Research shows that using virtual reality learning can deepen student comprehension through interactivity, greater context to the world, and a sense of scale and proximity that might not otherwise be possible. Snap’s AR technology offers endless possibilities for creativity, engagement and exploration. In traditional online learning environments, over half of students abandon their STEM courses before completion. To fill this gap, AR can aid in presenting complex concepts in a more tangible 3D format that empowers students to achieve their best. Through a partnership with Snap, Inspirit is hoping to make STEM learning more interactive and engaging for all students through their digital platform, the Innovative Learning Hub. Inspirit is creating 25 more Lenses powered by Snap AR focused on STEM curriculums that will be rolled out to at least 50 schools nationwide next school year. This exciting partnership was the focus of a nationwide media tour featuring Sophia Dominguez, the Director of AR Platform Partnerships & Ecosystem at Snap and Amrutha Vasan is the Co-Founder and COO of Inspirit include: Topics that they discussed during the media tour included: How augmented reality can supplement learning in the classroom. Ways that Snap’s AR technology offers endless possibilities for creativity, engagement and exploration. Partnership between Snap and Inspirit to bring immersive AR learning technology to classrooms to help revolutionize the way students learn. To learn more visit inspiritVR.com Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

November 07, 2023 09:47 AM Eastern Standard Time

Video
Article thumbnail News Release

Pursuing Excellence: Taiwan’s Academia Sinica Provides Fully-Funded Ph.D. Opportunities in 13 Advanced Disciplines through TIGP Program

Academia Sinica

TAIPEI, TAIWAN - Media OutReach - 7 November 2023 - Applications for the 2024 Fall semester for Taiwan International Graduate Program ( TIGP ) of Academia Sinica. The online application is open from 1st November 2023 to 1st February 2024 (GMT+8). Academia Sinica is the preeminent research institution in Taiwan. Its TIGP provides 13 interdisciplinary programs ranging from mathematical and physical sciences, life sciences to the humanities and social sciences. The all-English Ph.D. Program cooperates closely with Taiwan’s leading universities and provides superior scientific training courses. It is aimed to attract the top talents from around the world with ambition to grow personally and professionally. TIGP offers competitive financial support for its students. All admitted students enjoy a monthly stipend of NTD 40,000 (about USD 1,200) for the first year. For those who perform well, this stipend will be extended to the 2nd and the 3rd year. In subsequent years, financial support will come from the thesis advisor. Besides, full-time TIGP doctorate candidates or students who have passed their qualifying exams with distinction are eligible to apply for the TIGP Research Performance Fellowship. Awardees can receive an additional NTD 6,000 per month for one year. Through Academia Sinica’s substantial connections with first-rate institutions worldwide, TIGP can make arrangements for students to visit and conduct research in renowned laboratories around the globe. The yearly Travel Grant Award of TIGP encourages students to join important global symposiums. Other international exposure opportunities include attending seminars abroad, doing short-term research projects abroad, and participating in international meetings such as Lindau Nobel Laureate Meetings. Academia Sinica also invites distinguished scholars, entrepreneurial masters and Nobel Laureates to visit the campus and share their unique stories on achieving success in their respective fields. To facilitate first-year students’ quicker adaptation to the local environments, TIGP provides free-of-charge Mandarin language courses at the entry-level and a convenient and affordable fully-furnished dormitory. All the students of TIGP will find their experiences at Academia Sinica and in Taiwan not only personally rewarding but also culturally enriching. Application is free of charge through TIGP online system. For any questions, please visit the TIGP official website or contact Ms. Huan-Yi Shen with the TIGP Admission Office at tigp@gate.sinica.edu.tw. About TIGP Started in 2002, TIGP is a joint-effort between Academia Sinica and leading universities in Taiwan. It integrates first-class facilities with outstanding faculty to offer interdisciplinary Ph.D. programs across a wide range of disciplines. All courses are conducted in English. After completing the graduation requirements, students receive certificates from Academia Sinica and degrees from the partner universities. TIGP also periodically accepts applications for Taiwan International Internship Program (TIIP), a funded program which provides an opportunity for young talents to experience Academia Sinica’s research environment. In cooperation with 10 top domestic universities, the 13 interdisciplinary programs of TIGP are as follows: 1. Chemical Biology and Molecular Biophysics 2. Molecular Science and Technology 3. Molecular and Biological Agricultural Sciences 4. Bioinformatics 5. Molecular and Cell Biology 6. Nano Science and Technology 7. Molecular Medicine 8. Earth System Science 9. Biodiversity 10. Interdisciplinary Neuroscience 11. Sustainable Chemical Science and Technology 12. Social Networks and Human-Centered Computing 13. Artificial Intelligence of Things TIGP is a genuinely international community with over 579 students from 47 countries. To date, more than 769 students have completed TIGP’s rigorous requirements and obtained Ph.D. degrees. In the past years, TIGP students have published more than 2,349 research papers in top scholarly journals; many alumni have taken up teaching or research positions in world-renowned universities and academic institutions. TIGP graduates also proved themselves qualified to contribute their expertise to the industry. Many of them are now working in internationally well-known companies such as Samsung and TSMC. Academia Sinica has recently launched its National Biotechnology Research Park as a biotech industry corridor linking Taiwan to the global market. Right next to the campus of TIGP, the Park should shortly become a bridging platform of multidisciplinary research collaboration and occupational opportunities for the students. Academia Sinica - laying foundations for discovery As the leading government-funded research institute in Taiwan, Academia Sinica has spearheaded numerous fundamental and interdisciplinary research initiatives to address diverse challenges in Taiwan and beyond. Its key objectives, outlined by President James Liao, are to achieve global recognition, fulfil social responsibilities, and attract and cultivate top talent. These objectives are embedded in the diverse research programmes at AS, spanning life sciences, mathematics and physical sciences, as well as the humanities and social sciences. Contact Details Huan-Yi Shen tigp@gate.sinica.edu.tw

November 07, 2023 08:00 AM Eastern Standard Time

Article thumbnail News Release

Minuteman Press Franchise Owner Nil Patel Talks Leaving Corporate World, Celebrates Grand Opening in Solon, Ohio

Minuteman Press International Inc

After working in corporate finance, Nil Patel was looking for a career change. He shares, “I previously graduated from the University of Cincinnati with a bachelor’s degree in finance. After 8 years in the corporate world, I realized it was not for me. I wanted to be part of a company that helps others and be somewhere I can feel gratitude from the work I do!” Nil found what he was looking for in June of 2023 when he purchased the Minuteman Press franchise in Solon, Ohio. He explains, “I chose Minuteman Press because I wanted to be a part of a small business that has potential to grow and help other business thrive around me. The training and support from Minuteman Press International has been great! My RVP Rich DeRosa in particular has been extremely helpful and professional.” In September of 2023, Nil celebrated his grand opening; Minuteman Press in Solon is located at 33528 Aurora Road, Solon, OH 44139. Nil shares, “The community of Solon is a diverse blue-collar town where people are proud of the work they do! Our grand opening was a huge success. It was put together by the Solon Chamber of Commerce and I received extra help from my girlfriend and parents to really bring it all together. I’m excited to continue to serve and be a contributing member of the Solon community.” A few months into owning the business, Nil is happy with his progress as a business owner. He says, “I explain to clients that Minuteman Press in Solon is a full-service design, print, and marketing center serving the entire business community from small businesses to Fortune 500 companies. Our client base and business have been steady and we are growing.” Nil adds, “High-demand products that can help other local businesses/organizations grow are business cards, banners, flyers, and promo products – pens, calendars, koozies, flash drives, etc.” When asked about the industry and what he enjoys the most thus far, Nil answers, “Printing remains vital today because physical and digital advertising are both continuing to grow and this trend is going to continue.” He concludes, “Clients are looking for a healthy mix of both and I love that I can grow my business while helping others grow as well.” Minuteman Press in Solon, Ohio is located at 33528 Aurora Road, Solon, OH 44139. For more information, visit their website: https://minuteman.com/us/locations/oh/solon Learn more about #1 rated Minuteman Press franchise opportunities and read Minuteman Press franchise reviews at https://minutemanpressfranchise.com Contact Details Minuteman Press International Chris Biscuiti +1 631-249-1370 cbiscuiti@mpihq.com Company Website https://minutemanpressfranchise.com

November 06, 2023 10:00 AM Eastern Standard Time

Image
Article thumbnail News Release

Living with Acromegaly: Spreading Awareness and Highlighting Treatment Options on Acromegaly Awareness Day

YourUpdateTV

A video accompanying this announcement is available at: https://youtu.be/y696riLIIKs For more information, visit MYCAPSSA.COM Acromegaly is a rare condition that affects about 25,000 people living in the U.S. It is caused by a benign tumor in the pituitary gland which is located just beneath the brain. This benign tumor makes too much growth hormone, and this can cause various issues such as fatigue, headaches, and increased growth of hands and feet and pretty much every part of the body. If not treated, acromegaly can cause high blood sugar as in Diabetes and high blood pressure, and sometimes cause serious damage to the heart which can be life-threatening. The good news is that there are some very good treatments available to help control the problem. A nationwide media tour was conducted on October 23rd to discuss the drug MYCAPSSA as well as to hear about the experiences of someone living with acromegaly. The media tour featured Dr. Anthony P. Heaney, Professor at the David Geffen School of Medicine at the University of California, Los Angeles (UCLA) and Becky Bierman, a person living with acromegaly. Mycapssa, is a twice-daily oral medication that reduces the production of growth hormone and is designed for people who have previously been on an injectable version of octreotide therapy for the long-term maintenance of acromegaly. During the media tour Dr. Heaney and Becky discussed: · What acromegaly is and how many people it affects. · What it is like living with acromegaly. · Treatment options available for someone living with this disease. People diagnosed with acromegaly considering a new treatment option should talk to their doctors first. For more information, you can visit www.Mycapssa.com Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

November 01, 2023 09:57 AM Eastern Daylight Time

Video
Article thumbnail News Release

HKBU studies show over half of COVID-19 patients have post-disease syndrome

Hong Kong Baptist University

HONG KONG SAR - Media OutReach - 1 November 2023 - The School of Chinese Medicine at Hong Kong Baptist University (HKBU) found that 55% of the patients who sought medical treatment from the "HKBU Chinese Medicine Telemedicine Centre Against COVID-19" during the fifth wave of the COVID-19 pandemic continued to experience at least one long COVID symptom for six months to a year after diagnosed with an infection. The most common symptoms are fatigue, brain fog and cough. Professor Bian Zhaoxiang, Director of the Clinical Division at HKBU’s School of Chinese Medicine (middle), together with his research team members Mr Cheung Chun-hoi, Associate Director of the Clinical Division (2nd left); Dr Zhang Jialing, Postdoctoral Fellow of the Centre for Chinese Herbal Medicine Drug Development (1st left); Mr Luo Jingyuan and Wong Hoi-ki, PhD students (2nd and 1st right) of SCM at HKBU, analyse patient statistics to deepen the medical community’s understanding of the symptoms during the early and middle stages of COVID-19 infection as well as the post-COVID syndrome. The study also revealed that patients who took Chinese medicine after COVID-19 infection took a shorter time to test negative in rapid tests, and experienced significant symptom relief compared to patients who did not take Chinese medicine. The research findings have been published in a number of papers in international academic journals including the Journal of Medical Virology and The American Journal of Chinese Medicine. HKBU established the "HKBU Chinese Medicine Telemedicine Centre Against COVID-19" in 2021 during the fifth wave of the COVID-19 pandemic in Hong Kong to provide free telemedical services for COVID-19 patients. Making reference to the treatment protocols and clinical experiences in Mainland China, the expert team of HKBU's School of Chinese Medicine formulated the "Chinese Medicine Clinical Guidelines for COVID-19 in Hong Kong" as the University's clinical diagnosis and treatment standards for COVID-19. The Telemedicine Centre follows the guidelines to provide diagnosis, treatment, and prevention services to COVID-19 patients, close contacts, and caregivers. Coughing is the most common early symptom of infection The HKBU research team led by Professor Bian Zhaoxiang, Director of the Clinical Division at the School of Chinese Medicine, conducted a retrospective study using patient statistics collected by the Telemedicine Centre during the fifth wave of the pandemic. The team analysed the symptoms in the first four weeks of about 13,000 patients who were infected with COVID-19 from mid-March to early May in 2022 and underwent home isolation. The results showed that 93% of patients experienced at least one symptom. The most common symptoms during the first week of infection were cough (91%), sputum (75%), dry throat (50%) and sore throat (44%). 17% of patients still had these symptoms four weeks after infection. Although the symptoms gradually subsided over time, the prevalence of fatigue increased. Chinese medicine accelerates viral clearance Among this batch of patients, the research team selected 311 patients who had taken Chinese medicine for five days within 10 days after diagnosis, and another 311 patients who had not taken any Chine medicine during the same period to evaluate the efficacy of Chinese medicine. The results showed that patients who took Chinese medicine within 10 days after COVID-19 infection needed an average of seven days to test negative in rapid tests, and experienced an average of four symptoms, which were significantly milder compared to patients who didn't take Chinese medicine. The average time to test negative for patients who did not take Chinese medicine was eight days, and they experienced an average of 11 symptoms. The results show that Chinese medicine is an effective treatment for COVID-19 infection. Over half of the patients experience long COVID after six months The research team conducted a follow-up telephone survey from November 2022 to January 2023 with 6,242 COVID-19 patients who sought medical consultation at the Telemedicine Centre between December 2021 and May 2022 to understand their symptoms and risk factors after six months to a year of infection. The study found that 55% of patients still experienced at least one long-term symptom, i.e. "long COVID" or "post-COVID syndrome". The most common symptoms were fatigue (36%), brain fog (34%) and cough (31%). Furthermore, females, middle-aged persons, obese people, those with comorbidities such as ophthalmology or otorhinolaryngology diseases, digestive system diseases, respiratory diseases, hyperlipidemia and cardiovascular diseases, and patients with more initial symptoms were more likely to develop long COVID. However, there was no significant correlation between taking three or more doses of vaccine and the occurrence of long COVID. Professor Bian said: "HKBU established the Telemedicine Centre during the COVID-19 outbreak to provide free treatments for COVID-19 patients. We analysed the Centre's data to deepen the medical community's understanding of the symptoms during the early and middle stages of COVID-19 infection as well as the post-COVID syndrome. It allows the public to understand the effectiveness of Chinese medicine in treating COVID-19. The study also shows that the tele-services of Chinese medicine can be an important component of Hong Kong's healthcare and disease prevention system." To address the issues of long COVID, Professor Bian's team has initiated a series of clinical and basic research, including a survey of COVID-19 patients with diabetes and a clinical trial conducted in collaboration with other partners to investigate the efficacy, safety and action mechanism of senlingcao oral liquid in treating long COVID fatigue. These projects aim to further explore the impact of COVID-19 and its treatment options. Contact Details Christina Wu christinawu@hkbu.edu.hk

November 01, 2023 09:00 AM Eastern Daylight Time

Image
Article thumbnail News Release

How Ambow Education (NYSE: AMBO) Is Potentially Revolutionizing The Future Of Education With HybriU AI Digital Learning

Ambow Education Holding

By Faith Ashmore, Benzinga The world of education is rapidly evolving, largely due to changes in technology and an increased need for remote or hybrid learning. As a result, companies such as Ambow Education Holdings Ltd. (NYSE: AMBO) are stepping up to provide innovative solutions that address the changing needs of educators and students alike. Ambow’s HybriU AI digital education solution seems to be gaining attention and is being employed in a range of environments to achieve various goals. Ambow, a leading AI technology-driven educational company operating primarily in the United States, seems poised to transform education with its latest innovation – the HybriU AI digital education solution. This cutting-edge solution is powered by groundbreaking OOOK technology and is a patented system designed to modernize and elevate educational and workforce training for students. By harnessing this advanced technology, Ambow seeks to provide students with comprehensive and current resources, equipping them with the skills necessary to thrive in today’s rapidly evolving world. The online education sector seems to be on a trajectory for growth, projected to more than triple from its 2022 valuation of $192 billion to $602 billion by 2030, at a robust compound annual growth rate (CAGR) of 17.2% from 2022 to 2030. The distinct advantages offered by HybriU, tailor-made for the new hybrid learning paradigm, seem to position Ambow Education at the forefront of the industry. Ambow aims to be the driving force in the sector, propelling hybrid learning experiences into the future. One of HybriU's potential benefits is to bridge learning gaps within school districts. With its personalized learning capabilities, HybriU empowers educators to create customized educational content tailored to individual students' specific needs. This enables students to learn at their own pace and receive targeted support where they face challenges. Moreover, the solution ensures remote accessibility, which is particularly beneficial for students in rural or underserved communities who may otherwise lack access to high-quality educational resources. Another compelling use for HybriU lies in its ability to facilitate interactive hybrid teaching across multiple branches and sites. By transcending geographical boundaries, HybriU aims to foster a more engaging and dynamic learning experience for students across different locations and branches This flexible approach to education effectively extends the reach of universities and colleges beyond state and international borders, thereby granting access to a broader audience. Equally significant is HybriU's capability to provide data-driven insights, enabling educators to develop effective strategies for addressing learning gaps. By analyzing performance data, HybriU can pinpoint precisely where students encounter difficulties and provide teachers with invaluable insights into how best to support their students' specific learning needs. With the assistance of remedial and enrichment materials, HybriU can also provide students with targeted support to help them catch up in specific subjects or excel further. The HybriU AI digital education solution seems poised to be a transformative force in education, reshaping the landscape of learning. From closing learning gaps and improving accessibility to enabling interactive teaching across diverse educational environments, to many it comes as no surprise that HybriU is capturing attention and delivering desirable results for its users. As the field of education continues to evolve, solutions like HybriU can likely be expected to play a vital role in empowering educators and students to unlock their full potential. Ambow aims to be at the forefront of this educational revolution, driving the future of learning. To sign up for a free demo of HybriU, visit http://www.hybriU.com or www.ambow.com. Ambow Education Holding Ltd. is a leading cross-border career educational and technology service provider, offering high-quality, individualized services and products. With its extensive network of regional service hubs complemented by a dynamic proprietary learning platform and distributors, Ambow provides its services and products to students in China and United States of America. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Kevin Derrivan kderrivan@amboweducation.com Company Website https://www.ambow.com/

November 01, 2023 09:00 AM Eastern Daylight Time

1 ... 1718192021 ... 94